Myelodysplastic Syndromes — VA Disability Rating (DC 7725)
Diagnostic Code 7725 · 38 CFR §4.117
What Is It?
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders where the marrow produces blood cells that are abnormally shaped and do not function properly. The defective cells die in the marrow or shortly after entering the bloodstream, resulting in low blood counts across one or more cell lines — low red blood cells (causing fatigue and weakness), low white blood cells (increasing infection risk), and low platelets (causing easy bruising and bleeding). MDS primarily affects older adults and can range from mild, slow-progressing disease to aggressive forms that transform into acute myeloid leukemia. For veterans, MDS has strong associations with toxic exposures during military service. Benzene (found in fuels, solvents, and burn pit smoke), ionizing radiation, Agent Orange and other herbicides, and industrial chemicals are well-established risk factors. The latency period between exposure and MDS development can be decades, meaning the condition may not appear until many years after service. The VA rates MDS based on the treatment burden and the severity of blood count abnormalities.
Rating Criteria
| Rating | Criteria |
|---|---|
| 100% | High-risk MDS requiring intensive treatment or stem cell transplant evaluation, with frequent transfusion dependence, recurrent infections or bleeding episodes, or progression toward acute myeloid leukemia. |
| 60% | MDS requiring regular transfusions, disease-modifying agents (such as azacitidine or decitabine), or multi-lineage cytopenias causing significant anemia, infection susceptibility, and bleeding risk that substantially limit daily functioning. |
| 30% | MDS requiring intermittent red blood cell transfusions or regular growth factor injections to maintain adequate blood counts, with moderate symptoms of anemia and fatigue. |
| 10% | Low-risk MDS with mild reduction in one blood cell line, manageable with monitoring and possibly erythropoietin or other growth factors, without requiring transfusions. |
Evidence Needed
Bone marrow biopsy showing dysplastic changes across one or more cell lines is the diagnostic standard. Cytogenetic testing (chromosome analysis) helps classify the MDS subtype and risk category, which directly affects prognosis and treatment approach. Serial complete blood counts documenting the degree and persistence of cytopenias are essential. Transfusion records showing frequency and volume demonstrate severity. Treatment records for growth factors, disease-modifying drugs, or transplant planning document the treatment burden. For service connection, documentation of toxic exposure during service (deployment records, military occupational specialty, burn pit registry enrollment) and a hematology nexus opinion linking MDS to that exposure are important.
C&P Exam Tips
Describe your blood count levels and how frequently they are monitored. If you receive transfusions, explain how often, how long each session takes, and how you feel before and after. Describe the symptoms from each low cell line: fatigue and breathlessness from anemia, infections from low white cells, bruising and bleeding from low platelets. Explain how these combined deficits affect your daily life — MDS often impacts multiple functions simultaneously, which is different from having just one type of anemia. If you are on disease-modifying therapy, describe the treatment schedule and side effects. If your hematologist has discussed the risk of progression to acute leukemia, mention that — it demonstrates the seriousness and ongoing medical burden of the condition.
How to File
File on VA Form 21-526EZ with DC 7725. Submit bone marrow biopsy results, cytogenetic testing, serial blood counts, and transfusion records. Include documentation of in-service toxic exposure — deployment records, burn pit registry enrollment, military occupational records showing chemical or radiation exposure. A hematology nexus letter connecting MDS to the documented exposure is strongly recommended. Because MDS can appear decades after exposure, the nexus opinion should specifically address the known latency period for this condition.
Common Mistakes
The biggest mistake is not connecting MDS to in-service toxic exposure because of the long latency period — veterans and even some doctors may not realize that benzene exposure from 20 or 30 years ago can cause MDS today. A good hematology nexus opinion will explain this latency. Not documenting transfusion frequency in detail weakens the severity assessment. Not tracking and reporting every infection episode (which results from low white cells) leaves out evidence of the condition impact. Finally, if MDS progresses to acute leukemia, failing to update the claim to reflect the more serious diagnosis means missing the automatic 100 percent rating for active leukemia under DC 7703.
Frequently Asked Questions
Can MDS develop decades after toxic exposure?
Yes. MDS is well known for having a long latency period between the causative exposure and the onset of the disease. It is common for MDS to appear 10, 20, or even 30 years after benzene, radiation, or chemical exposure. This does not weaken your claim — a hematology nexus opinion can explain the established medical understanding of delayed onset.
What happens if MDS transforms into acute leukemia?
If MDS progresses to acute myeloid leukemia (AML), you should update your claim immediately. Active leukemia carries an automatic 100 percent rating under DC 7703. The existing service connection for MDS makes connecting the leukemia straightforward since it developed from the already service-connected condition.
Is MDS linked to burn pit exposure?
Benzene is a known risk factor for MDS, and benzene is present in burn pit smoke. The PACT Act expanded presumptive conditions for burn pit-exposed veterans. While not all MDS subtypes may be on the current presumptive list, a strong nexus opinion connecting burn pit benzene exposure to MDS development is a viable pathway to service connection.